Background: Idiopathic full-thickness macular holes
elderly. It is estimated that the condition affects 3 in 1000 individuals, 72 % of whom are women, usually in their sixth or seventh decade of life. 1 Hormonal imbalances 2 and high plasma fibrinogen3 have been noted in previous studies. There is now general agreement that vitreoretinal traction is all important in the development of FTMH. 4. 5 In 1988, Gass 6 described his observations on the pathogenesis of FTMH and suggested a classification of FTMHs which is now widely used. He pointed out that unlike peripheral retinal breaks, FTMHs are caused by tangential vitreoretinal traction. Initially, a focal detachment of the foveola occurs (stage I or impending hole), which may resolve spontaneously in up to 60% of cases? In others the continuing traction results in disintegration of the fovea and the appearance of a small FTMH with an overlying vitreous condensation (stage II). With time the FTMH usually enlarges, the edges become elevated by a cuff of subretinal fluid and a localised posterior vitreous separation occurs with a condensation ('operculum') lying in front of the retina (stage III). Eventually, with further vitreous detachment, the 'operculum' moves forward on the posterior vitreous cortex and may become difficult to find ophthalmo scopically (stage IV).
The importance of traction at the vitreoretinal interface has been further highlighted by retro spective 6 . 8 and prospective9 studies. Using kinetic B-scan ultrasonography Fisher et a l . 9 demonstrated that in patients with an established FTMH in one eye, the fellow eye with attached vitreous has a 12% risk of developing a macular hole. In contrast, none the fellow eyes with posterior vitreous separation at baseline went on to develop a FTMH.
Until recently, the management of FTMHs was mostly limited to observation. However, since Gass As in the previous reports, the operative procedure consisted of a three-port pars plana vitrectomy and peeling of the posterior cortical vitreous from the retinal surface using the aspiration cannula. No intraocular tamponade was used. After a minimum follow-up of 6 months, 2 (5%) patients had progressed to FTMH. In the first patient this was observed on the first post-operative day and in the second 4 months after the operation. Central vision was preserved or improved in the remaining 38 (95%) patients.
Although the results of such pilot studies appeared encouraging at first, they had to await confirmation by a controlled randomised treatment trial. In one such trial de Bustros et a i .7 compared vitrectomy for stage I macular hole with its natural history and found no statistical difference in the anatomical or visual outcomes (Table I) . However, as full recruit ment to this trial could not be concluded prior to the publication of the results, no definite recommenda tions as to the management of impending (stage I) macular holes can be offered. Neverthless, with this information and with the encouraging results of surgery for FTMH, the management of impending 6/ 6/ 9 6 with stage III holes and none of the 4 patients with stage IV holes (Fig. 1) . The change in the best corrected visual acuity reflected the closure rate of FTMH. Of the 9 patients with stage II holes, 6 (67%) had visual improvement, whereas only 2 of the 7 (29%) with stage III and none of the 4 with stage IV had improved vision ( Fig. 2 ; Table II ).
. It appeared that the earlier patients presented wIth early stages of FTMH, the better the visual results that could be obtained. Of the patients who presented within 3 weeks after !he onset of sy�p toms, 7 improved by 2 Snellen hnes or more, whtle only 1 patient who presented after 3 weeks did so. Visual acuity of 6/12 or better was obtained in 6 of 8 patients who presented within 3 weeks, but the same was true of only 4 of the 12 with later presentation (Table III) . Thus the favourable pre-operative characteristics were a shorter duration of symptoms and a smaller sized hole; this is in agreement with the results obtained in subsequent studies. 2 3
ADJUNCTIVE SUBSTANCES IN MACULAR HOLE SURGERY
Whereas smaller (stage II) FTMHs may be closed by a relatively simple surgical procedure, additional steps may be required for the treatment of the later stages of FTMH (stages III and IV). In 1992, Glaser et a l . I4 reported excellent results using bovine transforming growth factor beta (TGF-I3) in conjunc tion with vitrectomy and gas tamponade.I4 TGF-13 had previously been shown to be a potent stimulator of the synthesis of collagen and glycoprotein, as well (Table IV) .
It appears that closure of a FTMH is associated with a limited healing response. Proliferation of fibrous astrocytes3 6 and Mtiller cells37 has been demonstrated in histological studies of successfully treated eyes with FTMH. 5 Such a limited healing response may be encouraged by the use of adjunctive substances, such as autologous serum and the growth factors they contain. While this is a new and exciting development in ophthalmology, our enthusiasm must be tempered by the fact that other authors report similar results with vitrectomy and gas tamponade with strict post-operative face down positioning alone 19 (Table IV) . Controlled randomised treat ment trials designed to assess the usefulness of the various healing promoters are now in progress and we must await their results before deciding on the best treatment for our patients with FTMHs.
